Vycor Medical, Inc. VYCO
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.61% | 11.65% | 17.25% | 31.85% | 30.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.61% | 11.65% | 17.25% | 31.85% | 30.79% |
| Cost of Revenue | 18.58% | 48.31% | 81.24% | 84.50% | 73.04% |
| Gross Profit | -1.21% | 6.53% | 9.74% | 25.69% | 25.68% |
| SG&A Expenses | -1.41% | 0.67% | 7.44% | 10.90% | 15.81% |
| Depreciation & Amortization | -1.51% | -1.51% | 0.00% | 0.85% | 1.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.17% | 5.40% | 14.45% | 18.05% | 21.71% |
| Operating Income | 114.67% | 845.97% | 472.53% | 196.97% | 127.14% |
| Income Before Tax | 28.88% | 89.91% | 34.39% | 92.38% | 56.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.88% | 89.91% | 34.39% | 92.38% | 56.43% |
| Earnings from Discontinued Operations | -89.47% | -2,100.00% | -1,000.00% | 37.50% | 47.22% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.11% | 88.01% | 32.31% | 91.47% | 56.25% |
| EBIT | 114.67% | 845.97% | 472.53% | 196.97% | 127.14% |
| EBITDA | 27.93% | 198.65% | 77.19% | 605.59% | 505.16% |
| EPS Basic | 4.92% | 22.73% | 9.16% | 35.44% | 22.29% |
| Normalized Basic EPS | 21.43% | 90.48% | 35.00% | 94.44% | 60.00% |
| EPS Diluted | 5.69% | 21.97% | 8.40% | 34.81% | 21.66% |
| Normalized Diluted EPS | 26.67% | 85.71% | 30.00% | 91.67% | 57.14% |
| Average Basic Shares Outstanding | 0.35% | 0.91% | 1.49% | 2.07% | 1.92% |
| Average Diluted Shares Outstanding | -3.49% | 4.92% | 5.51% | 6.12% | 5.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |